Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

Study acronym: MAFASA
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Feb 1, 2027 → Feb 1, 2028
See other at-risk trials from Sonavex, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Feb 1, 2027 to Feb 1, 2028 Show 4 more changesShow less
    • Study sites: 21 to 23
    • Interventions: EchoMark/EchoSure (Device), Standard of Care (Procedure) to EchoMark/EchoSure (Device), Standard of Care (Procedure)
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 2 of 9 entries
  2. Primary and study completion dates: Feb 1, 2026 to Feb 1, 2027
    • Study sites: 20 to 21
    v12
  3. Study sites: 18 to 20v11
  4. Study sites: 17 to 18v10
  5. Study sites: 13 to 17v9
Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: Feb 1, 2025 to Feb 1, 2026
    • Study sites: 11 to 13
    v8
  2. Study sites: 8 to 11v7
  3. Study sites: 4 to 8v6
  4. Study sites: 2 to 4v5
  5. Study sites: 1 to 2v4
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 15, 2024 to Feb 21, 2024
    v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sonavex, Inc.
2 trials monitored
See 1 trial at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Chronic Kidney Disease
1,423 trials monitored
See 70 trials at risk
This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.
Trial Details
NCT Number NCT06190717
Lead Sponsor Sonavex, Inc.
Conditions
(from sponsor)		 Diabetes, End Stage Renal Disease
Related terms Diabetes Mellitus, Kidney Failure, Chronic
Enrollment 304 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov